CYGX Begins Marketing Custom-Cloned Single-Stranded DNA Expression System Kits.Business Editors/Health & Medical Writers HOUSTON--(BUSINESS WIRE)--Sept. 27, 2001 CytoGenix Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :CYGX) CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. Dr. Malcolm Skolnick announced that the company has begun marketing its proprietary single-stranded DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. (ODN ODN Oligodeoxynucleotide ODN Optical Distribution Network ODN Optical Data Network ODN Ordnance Datum Newlyn (UK mapping coordinate system) ODN Online Dictionary of Neuroscience ODN Olathe Daily News ) intracellular expression system in kit form for academic research and commercial development. The kit (CYGXes1.1(TM)) will be programmed in the CytoGenix lab to contain the calling sequence for the oligonucleotide specified by the researcher ordering the kit. The ssDNA expression system kits will be sold to both researchers from academic institutions under a materials transfer agreement, and to biotechs and pharmaceutical companies under exploratory licenses. Dr. Yin Chen, director of research for CytoGenix, explains, "Our intracellular ssDNA expression systems can express any one of thousands of antisense antisense, DNA or RNA manipulated in a laboratory so that its components (nucleotides) form a complementary copy of normal, or "sense," messenger RNA (mRNA; see nucleic acid). , catalytic DNA, triplex-forming oligonucleotide and aptamer sequences already discovered and under investigation. We are continuing to develop new expression systems for both research and clinical studies. We are particularly interested in applications against heart disease, cancer and viral diseases viral diseases Diseases caused by viruses. Long-term immunity usually follows viral childhood diseases (see chickenpox). The common cold recurs into adulthood because many different viruses cause its symptoms, and immunity against one does not protect against others. ." The ssDNA expression system has a number of advantages over synthetic ODNs in terms of therapeutics: 1) Once introduced into cells, it will produce ODNs continuously in a controlled manner; 2) It avoids problems caused by chemical modification In biochemistry, chemical modification is the technique of chemically reacting a protein or nucleic acid with chemical reagents. Chemical modification can have several goals, such as
n. An integrated bodily response to an antigen, especially one mediated by lymphocytes and involving recognition of antigens by specific antibodies or previously sensitized lymphocytes. effects; 3) It can produce ssDNA of any size; and 4) Comparable intracellular production of ssDNA via the Company's expression systems versus synthetic ODNs can save millions of dollars in costs. Dr. Skolnick elaborates, "We know our ssDNA expression system works. The proof of concept phase is over. We are now ready to develop our broad-base technology into important therapeutics to eliminate or ameliorate specific disorders. The introduction of this product documents a significant advance from pure research to developing a genomics platform from which additional products can begin to flow." "Our technology will serve to enable the hundreds of other genomics companies who are developing thousands of ODN sequences to complete and get approval for their therapeutic products," explains Board Chairman Dell Gibson. "This product rollout is designed to produce revenues, while at the same time increase market exposure and acceptance of the Company's technology by the genomics industry. This strategy will help generate a sound basis for future commercial licensing opportunities." CytoGenix Inc. is a Houston-based genomics research and development company with proprietary technology important in the advancement of various Oligonucleotide-Mediated Intervention (OMI (1) See Open Market. (2) (Open Microprocessor Initiative, Brussels, Belgium) An organization that functions under the umbrella of the European Commission. It funds projects that research and develop advanced microcontroller technologies. ) therapies. OMI therapies are those which impede the production of disease-causing proteins at their genetic origins through the introduction of specific single stranded DNA (ODN) sequences into the cells. SAFE HARBOR Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. : Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional technical information, pricing and license requirements are available by mail or on the Web at www.cytogenix.com, click on PRODUCTS. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion